REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal.

MLA

Batista, S., et al. “REALMS Study: Real-World Effectiveness and Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis in Portugal.” Neurological Sciences, vol. 42, no. 5, May 2021, pp. 1995–2003. EBSCOhost, https://doi.org/10.1007/s10072-020-04726-6.

APA

Batista, S., Nunes, C. C., Cerqueira, J. J., Martins Silva, A., Correia de Sá, J., Ferreira, J., Mendonça, M. T., Pinheiro, J., Salgado, V., Correia, A. S., Sequeira, J., Costa, A., & Sousa, L. (2021). REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal. Neurological Sciences, 42(5), 1995–2003. https://doi.org/10.1007/s10072-020-04726-6

Chicago

Batista, S., C. C. Nunes, J. J. Cerqueira, Ana Martins Silva, J. Correia de Sá, J. Ferreira, M. T. Mendonça, et al. 2021. “REALMS Study: Real-World Effectiveness and Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis in Portugal.” Neurological Sciences 42 (5): 1995–2003. doi:10.1007/s10072-020-04726-6.